Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and Drug ...
Inebilizumab showed significant efficacy in improving MG-ADL and QMG scores in gMG patients compared to placebo over 26 weeks. The trial included 238 patients, with 80% AChR+ and 20% MuSK+, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results